Intelligence Feed event · Equity · 2026-09-18

    Eli Lilly GLP-1 revenue reaches $27.7B in 1H 2026 as oral Foundayo expands PBM coverage

    Question

    Eli Lilly GLP-1 revenue reaches $27.7B in 1H 2026 as oral Foundayo expands PBM coverage

    Direct answer

    Eli Lilly (LLY) has experienced a 7% monthly share price correction despite demonstrating strong commercial execution, generating $27.7 billion in first-half 2026 revenue across its core GLP-1 treatments Mounjaro and Zepbound. Commercialization of its oral weight-loss asset Foundayo is expanding through formal adoption by major pharmacy benefit managers, while newer therapeutic assets grew 121% in Q2, broadening the company's revenue base beyond injectable metabolic therapies.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-18
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Eli Lilly GLP-1 revenue reaches $27.7B in 1H 2026 as oral Foundayo expands PBM coverage”, revision 1, evidence through 2026-09-18. https://marketontology.com/market-events/2026-09-18/eli-lilly-glp-1-revenue-reaches-27-7b-in-1h-2026-as-oral-foundayo-expands-pbm-co-298d67

    EQUITY
    Eli Lilly GLP-1 revenue reaches $27.7B in 1H 2026 as oral Foundayo expands PBM coverage
    Eli Lilly (LLY) has experienced a 7% monthly share price correction despite demonstrating strong commercial execution, generating $27.7 billion in first-half 2026 revenue across its core GLP-1 treatments Mounjaro and Zepbound. Commercialization of its oral weight-loss asset Foundayo is expanding through formal adoption by major pharmacy benefit managers, while newer therapeutic assets grew 121% in Q2, broadening the company's revenue base beyond injectable metabolic therapies.
    LLYXLV
    Impact
    69
    SEP 18
    SIG
    82%
    LLYXLV
    Eli Lilly GLP-1 revenue reaches $27.7B in 1H 2026 as oral Foundayo expands PBM coverage
    Eli Lilly (LLY) has experienced a 7% monthly share price correction despite demonstrating strong commercial execution, generating $27.7 billion in first-half 2026 revenue across its core GLP-1 treatments Mounjaro and Zepbound. Commercialization of its oral weight-loss asset Foundayo is expanding through formal adoption by major pharmacy benefit managers, while newer therapeutic assets grew 121% in Q2, broadening the company's revenue base beyond injectable metabolic therapies.
    → Expanded PBM formulary placement for Foundayo accelerates volume growth, stabilizing long-term cash flow multiples for LLY.
    Impact
    Eli Lilly (LLY) has experienced a 7% monthly share price correction despite demonstrating strong commercial execution, generating $27.7 billion in first-half 2026 revenue across its core GLP-1 treatments Mounjaro and Zepbound. Commercialization of its oral weight-loss asset Foundayo is expanding through formal adoption by major pharmacy benefit managers, while newer therapeutic assets grew 121% in Q2, broadening the company's revenue base beyond injectable metabolic therapies.
    Affected
    LLYXLV
    Transmission
    Expanded PBM formulary placement for Foundayo accelerates volume growth, stabilizing long-term cash flow multiples for LLY.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    LLYformulary expansion and volume uptake lifting forward cash flowUp1-3mSource details $27.7B in 1H sales and major PBM coverage wins for Foundayo.
    XLVheavy-weight constituent earnings supportUp1-4wEli Lilly's top-tier weighting within health care benchmark ETF.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    XLVUpagreed168.39 2026-09-18+0.37%+1.37%+4.94%

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month